v3.25.3

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2025	Dec. 31, 2024
Current assets:
Cash and cash equivalents	$ 272,639	$ 143,351
Marketable securities	0	73,952
Prepaid expenses and other current assets	7,285	4,036
Total current assets	279,924	221,339
Property and equipment, net	11,563	10,113
Operating right-of-use assets	3,125	4,278
Restricted cash	210	100
Other long-term assets	4,555	4,411
Total assets	299,377	240,241
Current liabilities:
Accounts payable	6,147	14,189
Accrued expenses and other current liabilities	25,298	33,177
Deferred revenue, current	0	6,941
Total current liabilities	31,445	54,307
Operating lease liabilities, net of current portion	4,013	4,769
Total liabilities	35,458	59,076
Commitments and contingencies (Note 7)
Stockholders' equity:
Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued or outstanding at September 30, 2025 and December 31, 2024
Common stock, $0.0001 par value; 300,000,000 shares authorized at September 30, 2025 and December 31, 2024; 91,706,948 and 64,460,829 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively	9	6
Additional paid-in capital	922,174	696,872
Accumulated other comprehensive income	0	57
Accumulated deficit	(658,264)	(515,770)
Total stockholders' equity	263,919	181,165
Total liabilities and stockholders' equity	$ 299,377	$ 240,241

Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

Immunome Inc. 10-Q